Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

2014 ACR/ARHP Annual Meeting: Innate Immunity at the Core of Rheumatic Disease

Kathy Holliman  |  Issue: March 2015  |  March 1, 2015

“It is important to recognize that nutrition and fitness have metabolic effects to decrease tissue AMPK activity that are quite pertinent to gout,” Dr. Terkeltaub said. Dietary and alcohol excesses, obesity, diabetes and poor physical fitness all have an effect, whereas nutritional constraint and physical fitness will elevate AMPK activity. Beyond colchicine, several drugs already in the clinic have the potential to limit innate immune inflammation, in large part, by activating AMPK. Those include methotrexate, nonacetylated salicylates, high-dose aspirin and metformin. “There is substantial potential for natural and pharmacologic means to limit harmful innate immune responses more safely and effectively by increasing tissue AMPK activity, such as in gout, osteoarthritis and certain other chronic joint diseases.”


Kathy L. Holliman, MEd, is a medical writer based in Beverly, Mass.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Second Chance

If you missed this session, Innate Immunity at the Core of Rheumatic Disease, it’s not too late. Catch it on SessionSelect: http://acr.peachnewmedia.com/store/provider/provider09.php.

References

  1. Steere AC, Malawista SE, Snydman DR, et al. Lyme arthritis: An epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum. 1977;20(1):7–17.
  2. Steere AC, Broderick TF, Malawista SE. Erythema chronic migrans and Lyme arthritis: Epidemiologic evidence for a tick vector. Am J Epidemiol. 1978;108(4):312–321.
  3. Malawista SE, de Boisfleury AC, Naccache PH. Inflammatory gout: Observations over a half-century. FASEB J.2011;25(12):4073–4078.
  4. Dalbeth N, Pool B, Gamble GD, et al. Cellular characterization of the gouty tophus. Arthritis Rheum. 2010;62(5):1549–1556.
  5. Schauer C, Janko C, Munoz LE, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med. 2014;20(5):511–517.
  6. Zhao X, Petursson F, Viollet B, Lotz M, et al. Peroxisome proliferator-activated receptor γ coactivator 1α and FoxO3A mediate chondroprotection by AMP-activated protein kinase. Arthritis Rheumatol. 2014;66(11):3073–3082.
  7. Wang Y, Viollet B, Terkeltaub R, Liu-Bryan R. AMP-activated protein kinase suppresses urate crystal-induced inflammation and transduces colchicine effects in macrophages. Ann Rheum Dis. 2014. doi: 10.1136/annrheumdis-2014-206074 [Epub ahead of print].
ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsGout and Crystalline ArthritisMeeting ReportsResearch Rheum Tagged with:ACR/ARHP Annual MeetingHollimanImmunityRheumatic DiseaseRheumatology Research Foundation

Related Articles

    Metabolic Biosensor Implicated in Gout

    February 1, 2015

    AMP-activated protein kinase may be link between nutritional excess, inflammation that leads to gout

    Difficult Gout

    July 1, 2007

    “Grandpapa’s Torments” was the Rodnan Commemorative Gout Print featured at the 2005 ACR/ARHP Annual Scientific Meeting.

    Lost and found

    Understanding the Role of Uric Acid in Gout

    September 6, 2022

    From the first substantial argument in the 19th century that uric acid played a role in gout, it took about 100 years for the medical community to accept its role in triggering acute inflammatory gout attacks. Two papers, both published in 1962, helped demonstrate the link between uric acid and acute gout attacks, quickly opening…

    Research Reveals Clues Into Inflammatory Process of Crystal Arthropathies Note Experts at the 2013 ACR/ARHP Annual Meeting

    March 1, 2014

    New studies clarify the roles of monosodium urate crystals in gout, calcium pyrophosphate crystals in osteoarthritis, and identify more effective potential therapies for patients

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences